Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In human hair follicle cultures, this study found that cyclohexyl salicylate, an OR2A4/7 agonist, promoted hair growth by delaying catagen development and expanding epithelial stem cell progeny, suggesting its potential as a non-drug hair loss treatment.

In a double-blind clinical trial, this study found that a gel containing chitosan-coated spironolactone nanoparticles effectively reduced acne lesions over 8 weeks without adverse skin effects, suggesting potential for enhanced acne treatment through targeted skin delivery.

This article discusses the potential for combining PROTACs with other therapeutic modalities in drug discovery and reports no clinical results.

This study found that ALRN-6924 effectively protected human hair follicles from cyclophosphamide-induced damage in an ex vivo setting, suggesting it may reduce both acute and permanent chemotherapy-induced alopecia.

This study reports that 2-(1-Adamantyl)-4H-thiochromen-4-on-6-O-sulfamate is the most potent steroid sulfatase inhibitor identified so far, exhibiting 170-fold higher activity than the lead compound estrone sulfamate.

The document concludes that a compound with potential for treating prostate cancer and hair loss was successfully made and its detailed structure was confirmed.

This study found that surface-modified liquid crystalline nanoparticles significantly enhanced skin permeation of finasteride and dutasteride compared to unmodified nanoparticles, suggesting potential for improved treatment efficacy in androgenetic alopecia.

This study reports that a low concentration of chitosan induces callose deposition and slows root hair growth in Arabidopsis, suggesting an evolutionary conservation of this response to mild biotic stress across plant types.

This invention reports piperazine derivatives as potent inhibitors of type 3 17β-hydroxysteroid dehydrogenase, suggesting potential therapeutic applications in treating prostate cancer, acne, and androgenic alopecia.

This study generated a pharmacophoric model for both isoforms of steroidal 5α-reductase using 6-azasteroids, providing a structural framework for designing new inhibitors.

This study introduces a novel visible light-mediated intramolecular [2+2] cycloaddition process that forms 6-azabicyclo[3.1.1]heptanes, offering a new synthesis route for bioisosteric mimetics used in drug discovery, potentially expanding medicinal chemistry applications beyond traditional limitations.

This study found that caffeic acid amide derivative, compound 4, effectively inhibited steroid 5α-reductase type 1 in vitro, suggesting potential for development as a treatment for androgenic alopecia.

In this study, researchers introduced a visible-light-mediated intramolecular cycloaddition method that selectively forms 6-azabicyclo[3.1.1]heptanes, suggesting these structures could offer promising new scaffolds for drug discovery and medicinal chemistry.

This review discusses the development and clinical progression of PROTAC technology for targeted protein degradation, highlighting its potential to address previously "undruggable" targets but reports no new clinical results.

A new, less toxic and more efficient method to create the anti-baldness compound RU58841 was developed in 2014.

This review highlights that clascoterone, a newly FDA-approved topical androgen antagonist, effectively reduces both non-inflammatory and inflammatory acne lesions with no systemic effects, making it a promising new option for acne treatment in both male and female patients.

This study found that in Arabidopsis root hairs, mild chitosan treatment triggered callose deposition and slowed growth, while a higher concentration inhibited growth without callose deposition, indicating different responses based on chitosan concentration.

This study found that the cosmetic olfactory receptor agonist cyclohexyl salicylate may stimulate hair growth and expand stem cell progeny, suggesting potential as a cosmetic adjuvant for hair loss.

In this study, researchers found that cepharanthine significantly inhibited the growth of non-small cell lung cancer cells by inducing apoptosis through ROS generation and altering multiple signaling pathways, suggesting potential as a novel lung cancer treatment.

This study optimized a screening assay to identify molecules that inhibit or enhance TRPM5 ion channel activity, which may have implications for treating dysfunctions linked to cardiac arrhythmias and diabetes.

This study identified AH01 derivatives and related compounds with high antischistosomal efficacy and reduced antiandrogenic effects, suggesting potential new directions for schistosomiasis drug development.

This study found that cephalanthine inhibited the growth of gastric cancer cells in vitro and in vivo by inducing oxidative stress and altering energy metabolism, suggesting its potential as a treatment for gastric cancer.

This study reported the development of new pyrazole-based MPC inhibitors that effectively inhibit mitochondrial pyruvate transport, showing potential as therapeutic candidates for conditions like metabolic dysfunction-associated steatohepatitis without activating PPARγ.

This review highlights the potential of PROTACs to transform cancer treatment by selectively degrading oncogenic proteins, overcoming drug resistance, and reducing toxicity; it also discusses challenges in optimizing these therapies for personalized applications.

This review discusses indole-based bifunctional aldose reductase inhibitors and antioxidants for diabetic complications and chronic inflammation-related pathologies, but reports no new clinical results.

In this study, researchers developed de novo designed hetero-bifunctional proteins as an alternative approach for targeted protein degradation, successfully targeting BCL-xL for degradation in cells and inducing apoptosis, which may expand the range of addressable E3 ligases and disease targets.

A new compound may effectively inhibit the enzyme linked to BPH and hair loss.

This review examines recent research on optimizing the structures of steroidal inhibitors for key steroidogenic enzymes used as cancer treatments, reporting on 209 new compounds with preclinical data that suggest structural modifications hold promise for developing new antineoplastic agents.

This study found that two synthesized androst-4-ene-3-one derivatives, 6f and 6g, exhibited stronger anti-proliferative effects than common drugs on prostate cancer cell lines, with low toxicity to rat cells.

This article explores the potential of chitin nanofibrils as a bioactive polymer for skin applications by examining their hydrophilic properties and effects on cell behavior, but presents no new experimental results.